[go: up one dir, main page]

ATE252639T1 - Modifizierter, das dorsalgewebe beeinflussender faktor - Google Patents

Modifizierter, das dorsalgewebe beeinflussender faktor

Info

Publication number
ATE252639T1
ATE252639T1 AT98936850T AT98936850T ATE252639T1 AT E252639 T1 ATE252639 T1 AT E252639T1 AT 98936850 T AT98936850 T AT 98936850T AT 98936850 T AT98936850 T AT 98936850T AT E252639 T1 ATE252639 T1 AT E252639T1
Authority
AT
Austria
Prior art keywords
factor affecting
modified factor
dorsal tissue
muteins
dorsal
Prior art date
Application number
AT98936850T
Other languages
English (en)
Inventor
Neil Stahl
Richard M Harland
Aris N Economides
Original Assignee
Regeneron Pharma
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Univ California filed Critical Regeneron Pharma
Application granted granted Critical
Publication of ATE252639T1 publication Critical patent/ATE252639T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT98936850T 1997-07-17 1998-07-17 Modifizierter, das dorsalgewebe beeinflussender faktor ATE252639T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/897,236 US6075007A (en) 1997-07-17 1997-07-17 Modified noggin polypeptide and compositions
PCT/US1998/014603 WO1999003996A1 (en) 1997-07-17 1998-07-17 Modified dorsal tissue affecting factor and compositions

Publications (1)

Publication Number Publication Date
ATE252639T1 true ATE252639T1 (de) 2003-11-15

Family

ID=25407592

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98936850T ATE252639T1 (de) 1997-07-17 1998-07-17 Modifizierter, das dorsalgewebe beeinflussender faktor

Country Status (10)

Country Link
US (3) US6075007A (de)
EP (1) EP1003860B1 (de)
JP (1) JP4181300B2 (de)
AT (1) ATE252639T1 (de)
AU (1) AU735851B2 (de)
CA (1) CA2296769C (de)
DE (1) DE69819167T2 (de)
HK (1) HK1026229A1 (de)
IL (2) IL134042A0 (de)
WO (1) WO1999003996A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL141330A0 (en) 1998-08-20 2002-03-10 Regeneron Pharma Dcr5, a bmp-binding protein and aplications thereof
ES2350454T3 (es) 1998-11-27 2011-01-24 Ucb Pharma S.A. Composiciones y métodos para incrementar la mineralización de la sustancia ósea.
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US20020159986A1 (en) * 2001-01-12 2002-10-31 John Langenfeld Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
WO2002087632A1 (en) * 2001-05-02 2002-11-07 Metaprobe, Inc. High throughput screening methods using magnetic resonance imaging agents
US20030134790A1 (en) * 2002-01-11 2003-07-17 University Of Medicine And Dentistry Of New Jersey Bone Morphogenetic Protein-2 And Bone Morphogenetic Protein-4 In The Treatment And Diagnosis Of Cancer
AU2003215297A1 (en) * 2002-02-15 2003-09-09 Cornell Research Foundation, Inc. Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concurrent overexpression of brain derived neurotrophic factor and an inhibitor of a pro-gliogenic bone morphogenetic protein
AU2003221841A1 (en) 2002-04-03 2003-10-27 Celltech R And D, Inc. Association of polymorphisms in the sost gene region with bone mineral density
JP4660471B2 (ja) 2003-03-14 2011-03-30 セルテック アール アンド ディー， インコーポレイテッド ＴＧＦβ結合タンパク質のリガンドおよびその使用
AU2004262640B2 (en) 2003-06-16 2010-12-23 Ucb Manufacturing, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
DK1773986T3 (en) * 2004-07-09 2019-04-08 Viacyte Inc PRE-PRIMATIVE STRIP AND MESENDODERM CELLS
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
AU2006289667A1 (en) * 2005-09-08 2007-03-15 Apollo Life Sciences Limited Noggin and chimeric molecules thereof
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
KR101163171B1 (ko) * 2009-01-20 2012-07-19 (주)케어젠 노긴?유래 펩타이드 및 그의 용도
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
DK2421957T3 (da) * 2009-04-22 2021-01-25 Viacyte Inc Cellesammensætninger afledt af dedifferentierede omprogrammerede celler
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
JP6043629B2 (ja) * 2011-01-07 2016-12-14 中外製薬株式会社 抗体の物性を改善させる方法
WO2012118903A2 (en) 2011-03-01 2012-09-07 Amgen Inc. Bispecific binding agents
MX338078B (es) 2011-03-25 2016-04-01 Amgen Inc Cristales de anticuerpos anti-esclerostina y formulaciones de los mismos.
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
PL2739311T3 (pl) 2011-08-04 2018-08-31 Amgen Inc. Metoda leczenia szczelinowych uszkodzeń kości
WO2013101451A1 (en) 2011-12-28 2013-07-04 Amgen Inc. Method of treating alvelor bone loss through the use of anti-sclerostin antibodies
WO2014006100A1 (en) 2012-07-05 2014-01-09 Ucb Pharma S.A. Treatment for bone diseases
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
MA40354A (fr) 2014-07-18 2017-05-24 Sanofi Sa Procédé permettant de prédire le résultat d'un traitement avec de l'aflibercept d'un patient suspecté de souffrir d'un cancer
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
EP3471754A1 (de) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1-antikörper
EP3534947A1 (de) 2016-11-03 2019-09-11 Kymab Limited Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
JP7405764B2 (ja) 2018-03-30 2023-12-26 アムジエン・インコーポレーテツド Ｃ末端抗体改変体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256568A (en) 1990-02-12 1993-10-26 Regeneron Phamaceuticals, Inc. Vectors and transformed most cells for recombinant protein production with reduced expression of selectable markers
EP0550665B1 (de) 1990-09-25 1996-07-31 Genentech, Inc. Neuer neurotropischer faktor
WO1994005791A2 (en) * 1992-09-03 1994-03-17 Regeneron Pharmaceuticals, Inc. Dorsal tissue affecting factor and compositions
AU5125693A (en) * 1992-09-03 1994-03-29 Regents Of The University Of California, The Dorsal tissue affecting factor and compositions

Also Published As

Publication number Publication date
DE69819167T2 (de) 2004-07-22
WO1999003996A1 (en) 1999-01-28
CA2296769A1 (en) 1999-01-28
AU735851B2 (en) 2001-07-19
AU8570898A (en) 1999-02-10
IL134042A (en) 2006-12-10
EP1003860A1 (de) 2000-05-31
US20030129703A1 (en) 2003-07-10
JP4181300B2 (ja) 2008-11-12
US6500640B1 (en) 2002-12-31
JP2001510044A (ja) 2001-07-31
DE69819167D1 (de) 2003-11-27
HK1026229A1 (en) 2000-12-08
EP1003860B1 (de) 2003-10-22
US6075007A (en) 2000-06-13
IL134042A0 (en) 2001-04-30
CA2296769C (en) 2008-01-15

Similar Documents

Publication Publication Date Title
ATE252639T1 (de) Modifizierter, das dorsalgewebe beeinflussender faktor
DK0691980T3 (da) 7-deazapurinmodifiderende oligonukleotider
ID26326A (id) Deripat-deripat 2 purin 9 il tetrahiderofuran 3,4 diol
DK0960127T3 (da) Isoleret dimert fibroblastaktiverende protein-alfa og anvendelser deraf
IL106894A0 (en) Dorsal tissue affecting factor and compositions
WO1999051731A3 (en) Maize histone deacetylases and their use
DK1123414T3 (da) Antisense-modulering af integrin alpha 4.ekspression
IT1293691B1 (it) Stent per angioplastica, particolarmente per il trattamento di vasi presentanti biforcazioni.
NO20013102L (no) Gener, proteiner og deres anvendelse
EP1163373A4 (de) Antisense-modulation des zellulären hemmstoffs der apoptosis-expression
ATE291586T1 (de) Humanes antibiotisches protein
IL139604A0 (en) Novel peptides
PE20399A1 (es) Muteina ob
IT242987Y1 (it) Guarnitura per mobili.
AP2006003504A0 (en) Outer surface proteins, their genes, and their use.
EP1096927A4 (de) Zusammensetzung für stressbehandlung
DE10081621D2 (de) Promotorsystem, dessen Herstellung und Verwendung
DE69828906D1 (de) Herstellung von 1,3 propandiolestern
DE69823022D1 (de) Neues, menschliches tumorsuppressorgen.
NO940896L (no) Fjernbar, ortopedisk brudd-stabilisator
AP2005003413A0 (en) Genes and proteins, and their use.
CA2143442A1 (en) Dorsal tissue affecting factor and compositions
ITFO980026U1 (it) Perfezionamenti nelle basi per ponteggi mobili.
SE9704723D0 (sv) Ligands
ES1034050Y (es) Un clavo de implantacion en fracturas oseas, mejorado.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1003860

Country of ref document: EP

REN Ceased due to non-payment of the annual fee